Eliasson, Björn http://orcid.org/0000-0003-2569-4160
Allansson Kjölhede, Elin
Salö, Sofia
Fabrin Nielsen, Nick
Eeg-Olofsson, Katarina
Funding for this research was provided by:
Sveriges Kommuner och Regioner
Novo Nordisk Scandinavia AB
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Article History
Received: 20 February 2024
Accepted: 21 March 2024
First Online: 10 April 2024
Declarations
:
: Björn Eliasson reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Mundipharma, Novo Nordisk and Sanofi, all outside the submitted work. Elin Allansson Kjölhede declare no conflict of interest relevant to this article. Sofia Salö and Nick Fabrin Nielsen are employed by NovoNordisk. However, the views expressed in this study are their own and not those of NovoNordisk. Katarina Eeg-Olofsson has received personal lecture fees and/or honoraria for consulting from Sanofi, Eli Lilly, Novo Nordisk and Abbott, all outside the submitted work.
: Approval for this study was granted by the Swedish Ethical Review Authority (diary numbers 2021-03236 and 2021-05785-02). In adherence to Swedish law (Patient Data Act 2008:355, chapter 7), individual consent is not necessary to report patients to national healthcare quality registries or to enroll them in this study. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.